Peanut Allergy clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for

  • Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

    Sorry, in progress, not accepting new patients

    The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.

    San Francisco, California and other locations

Our lead scientists for Peanut Allergy research studies include .